{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:13:15Z","timestamp":1785942795958,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"DOI":"10.7759\/cureus.114008","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:35:03Z","timestamp":1785940503000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Hematological Malignancies: A Narrative Review of Current and Emerging Evidence"],"prefix":"10.7759","author":[{"given":"Hari","family":"Krishnan Nair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti F","year":"2026","unstructured":"Celletti F, Farrar J, De Regil L. World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. 2026, 335:434-8. 10.1001\/jama.2025.24288","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003969","article-title":"Disease burden of hematological malignancies worldwide, in China and in the United States based on the GLOBOCAN 2022 and Global Burden of Disease 2021 data","volume":"139","author":"Lin M","year":"2026","unstructured":"Lin M, Sun W, Huang X, Zhao X. Disease burden of hematological malignancies worldwide, in China and in the United States based on the GLOBOCAN 2022 and Global Burden of Disease 2021 data. Chin Med J (Engl). 2026, 139:1042-53. 10.1097\/CM9.0000000000003969","journal-title":"Chin Med J (Engl)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32109","article-title":"Anthropometric characteristics, physical activity and risk of hematological malignancies: a systematic review and meta-analysis of cohort studies","volume":"145","author":"Psaltopoulou T","year":"2019","unstructured":"Psaltopoulou T, Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Riza E, Dimopoulos MA. Anthropometric characteristics, physical activity and risk of hematological malignancies: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2019, 145:347-59. 10.1002\/ijc.32109","journal-title":"Int J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz045","article-title":"Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies","volume":"30","author":"Abar L","year":"2019","unstructured":"Abar L, Sobiecki JG, Cariolou M, et al.. Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies. Ann Oncol. 2019, 30:528-41. 10.1093\/annonc\/mdz045","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0206","article-title":"Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma","volume":"15","author":"Lichtman MA","year":"2010","unstructured":"Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010, 15:1083-101. 10.1634\/theoncologist.2010-0206","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362830","article-title":"Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies","volume":"119","author":"Castillo JJ","year":"2012","unstructured":"Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012, 119:4845-50. 10.1182\/blood-2011-06-362830","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05338-7","article-title":"Association between diabetes and haematological malignancies: a population-based study","volume":"64","author":"Gong IY","year":"2021","unstructured":"Gong IY, Cheung MC, Read S, Na Y, Lega IC, Lipscombe LL. Association between diabetes and haematological malignancies: a population-based study. Diabetologia. 2021, 64:540-51. 10.1007\/s00125-020-05338-7","journal-title":"Diabetologia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1643-x","article-title":"Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells","volume":"53","author":"Hadjiyanni I","year":"2010","unstructured":"Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia. 2010, 53:730-40. 10.1007\/s00125-009-1643-x","journal-title":"Diabetologia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting","volume":"48","author":"K\u00f6rner M","year":"2007","unstructured":"K\u00f6rner M, St\u00f6ckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007, 48:736-43. 10.2967\/jnumed.106.038679","journal-title":"J Nucl Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf251","article-title":"Glucagon-like peptide-1 receptor signaling deficiency exacerbates hematopoietic stem cell graft rejection in mice","volume":"215","author":"Rusznak M","year":"2026","unstructured":"Rusznak M, Sierra-Hernandez D, Dupuy C, et al.. Glucagon-like peptide-1 receptor signaling deficiency exacerbates hematopoietic stem cell graft rejection in mice. J Immunol. 2026, 215:vkaf251. 10.1093\/jimmun\/vkaf251","journal-title":"J Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13674","article-title":"Obesity, bone marrow adiposity, and leukemia: time to act","volume":"25","author":"Kumar V","year":"2024","unstructured":"Kumar V, Stewart JH 4th. Obesity, bone marrow adiposity, and leukemia: time to act. Obes Rev. 2024, 25:e13674. 10.1111\/obr.13674","journal-title":"Obes Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152822","article-title":"GLP-1 receptor agonists and inflammatory pathway modulation: dual targeting of metabolic and immune dysfunction in insulin resistance","volume":"789","author":"Ngabea MA","year":"2025","unstructured":"Ngabea MA, Dimeji IY. GLP-1 receptor agonists and inflammatory pathway modulation: dual targeting of metabolic and immune dysfunction in insulin resistance. Biochem Biophys Res Commun. 2025, 789:152822. 10.1016\/j.bbrc.2025.152822","journal-title":"Biochem Biophys Res Commun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118065","article-title":"Immunomodulatory effects of anti-diabetic therapies: cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013-2025)","volume":"299","author":"Ullah A","year":"2025","unstructured":"Ullah A, Shen B. Immunomodulatory effects of anti-diabetic therapies: cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013-2025). Eur J Med Chem. 2025, 299:118065. 10.1016\/j.ejmech.2025.118065","journal-title":"Eur J Med Chem"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","author":"Ros-Madrid I","year":"2025","unstructured":"Ros-Madrid I, Cano-M\u00e1rmol R, Ferrer-Gomez M, Ramos-Molina B. Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. Can J Physiol Pharmacol. 2025, 103:369-77. 10.1139\/cjpp-2025-0148","journal-title":"Can J Physiol Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2026.117063","article-title":"NLRP3 inflammasome as a central target for the pleiotropic effects of GLP-1 receptor agonists","volume":"186","author":"Mahmoudi A","year":"2026","unstructured":"Mahmoudi A, Saeedi-Boroujeni A, Vadizadeh A, Kesharwani P, Sahebkar A. NLRP3 inflammasome as a central target for the pleiotropic effects of GLP-1 receptor agonists. Int Immunopharmacol. 2026, 186:117063. 10.1016\/j.intimp.2026.117063","journal-title":"Int Immunopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2026.0859","article-title":"The National Psoriasis Foundation primer on GLP-1 receptor agonists in psoriasis: a review","volume":"162","author":"Sheth S","year":"2026","unstructured":"Sheth S, Merola JF, Weber BN, et al.. The National Psoriasis Foundation primer on GLP-1 receptor agonists in psoriasis: a review. JAMA Dermatol. 2026, 162:619-30. 10.1001\/jamadermatol.2026.0859","journal-title":"JAMA Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0802","article-title":"Hematologic cancers among patients with type 2 diabetes prescribed GLP-1 receptor agonists","volume":"8","author":"Ashruf OS","year":"2025","unstructured":"Ashruf OS, Hundal J, Mushtaq A, Kaelber DC, Anwer F, Singh A. Hematologic cancers among patients with type 2 diabetes prescribed GLP-1 receptor agonists. JAMA Netw Open. 2025, 8:e250802. 10.1001\/jamanetworkopen.2025.0802","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1039\/d5fo03273c","article-title":"GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies","volume":"16","author":"Luo Y","year":"2025","unstructured":"Luo Y, Xu H, Zhao Y, Yang B, Zhang Y. GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies. Food Funct. 2025, 16:8943-64. 10.1039\/d5fo03273c","journal-title":"Food Funct"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2026.2654735","article-title":"GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence","volume":"22","author":"Frey C","year":"2026","unstructured":"Frey C. GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence. Future Oncol. 2026, 22:1221-31. 10.1080\/14796694.2026.2654735","journal-title":"Future Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103749","article-title":"Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records","volume":"91","author":"Irons EE","year":"2026","unstructured":"Irons EE, Pfeil KA, Perez JA, van Besien K. Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records. EClinicalMedicine. 2026, 91:103749. 10.1016\/j.eclinm.2025.103749","journal-title":"EClinicalMedicine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI202856","article-title":"Targeting GLP1R and IL17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model","author":"Kapur R","year":"2026","unstructured":"Kapur R, Li L, Kanumuri R, et al.. Targeting GLP1R and IL17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. J Clin Invest. 2026, 10.1172\/JCI202856","journal-title":"J Clin Invest"},{"key":"ref22","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes","volume":"44","author":"Chen WH","year":"2026","unstructured":"Chen WH, Radwan RM, Salman H, et al.. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes. J Clin Oncol. 2026, 44:6592.","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/biom15111622","article-title":"Divergent risks of hematologic malignancies associated with GLP-1 receptor agonists and SGLT2 inhibitors: preliminary findings from a pilot network meta-analysis","volume":"15","author":"Lin PY","year":"2025","unstructured":"Lin PY, Zeng BY, Hsu CW, et al.. Divergent risks of hematologic malignancies associated with GLP-1 receptor agonists and SGLT2 inhibitors: preliminary findings from a pilot network meta-analysis. Biomolecules. 2025, 15:1622. 10.3390\/biom15111622","journal-title":"Biomolecules"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-026-01788-5","article-title":"Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants","volume":"19","author":"Lin PY","year":"2026","unstructured":"Lin PY, Zeng BS, Chen JJ, et al.. Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants. J Hematol Oncol. 2026, 19:23. 10.1186\/s13045-026-01788-5","journal-title":"J Hematol Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-02237","article-title":"Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis","volume":"179","author":"Ko A","year":"2026","unstructured":"Ko A, Chang YC, Bahar F, et al.. Risk for cancer with glucagon-like peptide-1 receptor agonists and dual agonists: a systematic review and meta-analysis. Ann Intern Med. 2026, 179:216-29. 10.7326\/ANNALS-25-02237","journal-title":"Ann Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2026.113158","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis","volume":"234","author":"Ateiwi YA","year":"2026","unstructured":"Ateiwi YA, Mahmood R, Wong HJ, et al.. Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026, 234:113158. 10.1016\/j.diabres.2026.113158","journal-title":"Diabetes Res Clin Pract"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.17541","article-title":"GLP-1 RA use and major adverse cardiovascular events in patients with monoclonal gammopathy of undetermined significance","volume":"8","author":"Chi KY","year":"2025","unstructured":"Chi KY, Song J, Desphande S, et al.. GLP-1 RA use and major adverse cardiovascular events in patients with monoclonal gammopathy of undetermined significance. JAMA Netw Open. 2025, 8:e2517541. 10.1001\/jamanetworkopen.2025.17541","journal-title":"JAMA Netw Open"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.8124","article-title":"Diagnosis and management of monoclonal gammopathy of undetermined significance: a review","volume":"185","author":"Liu Y","year":"2025","unstructured":"Liu Y, Parks AL. Diagnosis and management of monoclonal gammopathy of undetermined significance: a review. JAMA Intern Med. 2025, 185:450-6. 10.1001\/jamainternmed.2024.8124","journal-title":"JAMA Intern Med"},{"key":"ref29","article-title":"The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes","volume":"127","author":"Juranovic T","year":"2025","unstructured":"Juranovic T, Tomanguillo Chumbe J, Aibani R, et al.. The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes. J Clin Oncol. 2025, 127:7559.","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70140","article-title":"GLP-1 receptor agonists in patients with MGUS: a real-world propensity-matched study","volume":"56","author":"Tentolouris A","year":"2026","unstructured":"Tentolouris A, Ntanasis-Stathopoulos I, Filippatos C, et al.. GLP-1 receptor agonists in patients with MGUS: a real-world propensity-matched study. Eur J Clin Invest. 2026, 56:e70140. 10.1111\/eci.70140","journal-title":"Eur J Clin Invest"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.7571","article-title":"Exploratory associations between incretin-based therapies and plasma cell disorders in patients with type 2 diabetes: A real-world study","volume":"44","author":"Ateiwi Y","year":"2026","unstructured":"Ateiwi Y, Al Tamimi MA, Alkuttob L, et al.. Exploratory associations between incretin-based therapies and plasma cell disorders in patients with type 2 diabetes: A real-world study. J Clin Oncol. 2026, 44:7571. 10.1200\/JCO.2026.44.16_suppl.7571","journal-title":"J Clin Oncol"},{"key":"ref32","article-title":"Association of GLP-1 receptor agonist exposure with mortality, infectious, and hematologic outcomes in chronic lymphocytic leukemia: A real-world retrospective TriNetX study","volume":"44","author":"Vemula SS","year":"2026","unstructured":"Vemula SS, Afridi SS, Shah N, et al.. Association of GLP-1 receptor agonist exposure with mortality, infectious, and hematologic outcomes in chronic lymphocytic leukemia: A real-world retrospective TriNetX study. J Clin Oncol. 2026, 44:18591.","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e19538","article-title":"Impact of glucagon-like peptide-1 receptor agonists on morbidity and mortality in multiple myeloma patients with type 2 diabetes mellitus: A retrospective cohort analysis","volume":"43","author":"Albliwi M","year":"2025","unstructured":"Albliwi M, Aloweiwi W, Yaghi R, et al.. Impact of glucagon-like peptide-1 receptor agonists on morbidity and mortality in multiple myeloma patients with type 2 diabetes mellitus: A retrospective cohort analysis. J Clin Oncol. 2025, 43:e19538.","journal-title":"J Clin Oncol"},{"key":"ref34","article-title":"Real-world outcomes comparing the use of GLP-1 agonists in patients with multiple myeloma and comorbid obesity: a propensity score-matched analysis from a global federated health research network","volume":"44","author":"Syal A","year":"2026","unstructured":"Syal A, Arya Y, Mahadevia H, et al.. Real-world outcomes comparing the use of GLP-1 agonists in patients with multiple myeloma and comorbid obesity: a propensity score-matched analysis from a global federated health research network. J Clin Oncol. 2026, 44:484.","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf703","article-title":"GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization","volume":"111","author":"Mahadevan A","year":"2026","unstructured":"Mahadevan A, Vosooghi A, Arora JS, Kumar RS, Singh G, Tsai KK, Quandt Z. GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. J Clin Endocrinol Metab. 2026, 111:1604-12. 10.1210\/clinem\/dgaf703","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178290","article-title":"Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients","volume":"1007","author":"Wawrzak-Pienkowska K","year":"2025","unstructured":"Wawrzak-Pienkowska K, Pienkowski T, Golonko A, et al.. Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients. Eur J Pharmacol. 2025, 1007:178290. 10.1016\/j.ejphar.2025.178290","journal-title":"Eur J Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: A systematic review and meta-analysis","volume":"17","author":"Nagendra L","year":"2023","unstructured":"Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023, 17:102834. 10.1016\/j.dsx.2023.102834","journal-title":"Diabetes Metab Syndr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01135-0","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown","volume":"23","author":"Mannucci E","year":"2026","unstructured":"Mannucci E, Dicembrini I. Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown. Nat Rev Clin Oncol. 2026, 23:459-70. 10.1038\/s41571-026-01135-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-026-10691-1","article-title":"GLP-1 receptor agonists during chemotherapy and radiotherapy: a supportive care call for nutrition-centred monitoring in the era of widespread prescribing","volume":"34","author":"Alati A","year":"2026","unstructured":"Alati A, Scher N, Toledano A. GLP-1 receptor agonists during chemotherapy and radiotherapy: a supportive care call for nutrition-centred monitoring in the era of widespread prescribing. Support Care Cancer. 2026, 34:10.1007\/s00520-026-10691-1","journal-title":"Support Care Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck MA","year":"2026","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, Bl\u00fcher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026, 407:892-908. 10.1016\/S0140-6736(25)02105-1","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S013","article-title":"13. Older adults: standards of care in diabetes - 2026","volume":"49","year":"2026","unstructured":"13. Older adults. standards of care in diabetes - 2026. Diabetes Care. 2026, 49:S277-96. 10.2337\/dc26-S013","journal-title":"Diabetes Care"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-026-04458-z","article-title":"Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer (online ahead of print)","author":"Muscogiuri G","year":"2026","unstructured":"Muscogiuri G, Del Vecchio G, Colangeli L, Guglielmi V, Sbraccia P, Colao A. Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer (online ahead of print). Intern Emerg Med. 2026, 10.1007\/s11739-026-04458-z","journal-title":"Intern Emerg Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-024-01494-5","article-title":"Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types","volume":"47","author":"Ungvari Z","year":"2025","unstructured":"Ungvari Z, Bartha \u00c1, Ungvari A, Fekete M, Bianchini G, Gy\u0151rffy B. Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types. Geroscience. 2025, 47:4413-27. 10.1007\/s11357-024-01494-5","journal-title":"Geroscience"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/520670-glucagon-like-peptide-1-glp-1-based-therapies-and-hematological-malignancies-a-narrative-review-of-current-and-emerging-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:35:05Z","timestamp":1785940505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/520670-glucagon-like-peptide-1-glp-1-based-therapies-and-hematological-malignancies-a-narrative-review-of-current-and-emerging-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.114008","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}